Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights
More than 70% of surveyed U.S. ophthalmologists anticipate a fundamentally transformed approach to managing nAMD and DME within the next five years. Exton, PA, July 10, 2025 — Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related macular degeneration (nAMD) and diabetic […]
Market Barriers Continue to Challenge PNH Treatment Optimization Despite Emerging Options, According to Spherix Global Insights
New research highlights significant insurance-driven hurdles, increasing second-line uptake of Fabhalta (Novartis), and strong physician interest in pipeline therapies including zaltenibart (Omeros), pozelimab-cemdisiran (Regeneron/Alnylam), and ruxaprubart (NovelMed). EXTON, PA, July 8, 2025 – Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder that can affect individuals of any age, race, or gender, though it is most […]
Pulmonologists and Rheumatologists Struggle to Diagnose and Manage CTD-ILD, According to New Research from Spherix Global Insights
Systemic sclerosis and myositis interstitial lung disease subtypes flagged as most difficult to manage; specialists cite lack of effective treatments and diagnostic clarity EXTON, PA, June 17, 2025 — According to Spherix Global Insights’ newly published Special Topix™: Interstitial Lung Disease in Rheumatology (US) report, both rheumatologists and pulmonologists report significant challenges in diagnosing and […]
Hematologists Set the Stage for Market Disruption as Next-Gen Hemophilia Therapies Gain Traction
New data released from Spherix Global Insights highlights exciting opportunities in both EU and US for launch brands Hympavzi (Pfizer), Alhemo (Novo Nordisk), Qfitlia (Sanofi) and others, along with emerging gene therapies. EXTON, P.A., June 11, 2025 – As the hemophilia landscape continues to transform, new research from Spherix Global Insights reveals a market on […]
New Spherix Global Insights Data Reveals 85% of FSGS Patients Have Actively Progressing Disease Despite Treatment, Underscoring Urgent Demand for Innovative Treatments
Findings from Spherix’s fourth annual patient chart audit of more than 500 FSGS patients reveal not only a large unmet need in this market, but also optimism about the future – especially for pipeline agents coming from Travere, Novartis, Vertex, Apellis and Dimerix. EXTON, PA – June 10, 2025 – Patients battling focal segmental glomerulosclerosis […]
As Interest Grows for New Agents to Treat Thalassemia, Hematologists Begin Early Identification of Ideal Patients for Gene Therapies Vs. New Therapeutic Options
Spherix Global Insights’ new patient audit on transfusion-dependent thalassemia reveals strong physician interest in emerging treatments like mitapivat and etavopivat, and provides insight into ideal candidates for curative gene therapies. [Exton, PA, June 04, 2025] – Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex) and Zynteglo (bluebird bio), most […]
Johnson & Johnson’s Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global Insights
Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists EXTON, PA, April 14, 2025 – Johnson & Johnson’s recent announcement of positive Phase 3 data for its oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), has sparked notable enthusiasm across the dermatology community. According to the company’s recent release, […]
A Glimpse Inside the CLE Pipeline: What’s Coming Down the Pike?
Dermatologists rely heavily on topical therapies for cutaneous lupus erythematosus (CLE), but are increasingly interested in systemic agents with user-friendly formulations and dermatology-relevant experience such as deucravacitinib (Sotyktu BMS), an oral TYK2 inhibitor currently approved for psoriasis. Familiarity with its mechanism and a favorable safety profile have positioned deucravacitinib as a top contender for future […]
Specialists Set Sights on CLE Pipeline as Unmet Needs Persist and Candidate Pool Expands, According to Spherix Global Insights
Rheumatologists and dermatologists highlight Saphnelo, Sotyktu, and litifilimab as leading candidates to address unmet needs in CLE patients, particularly those with systemic involvement Exton, PA., April 10, 2025 – As treatment approaches for cutaneous lupus erythematosus (CLE) continue to evolve, new data from Spherix Global Insights shed light on how specialists are currently managing the […]
Timely Findings Highlight Increased US Physician Familiarity with IRA Changes Amid Ongoing Reimbursement and Education Concerns, According to Spherix Global Insights
Recently released research reveals key insights into physician perspectives, practice management changes, and expected prescribing changes resulting from recent IRA-driven Medicare changes. EXTON, PA., April 10, 2025 — In 2025, the Inflation Reduction Act (IRA) introduced significant Medicare reforms designed to reduce financial burdens for patients, including a new cap on out-of-pocket (OOP) prescription drug […]
